Anaphylaxis V2

This is a revision of the Brighton Collaboration Case Definition of the term “Anaphylaxis” to be utilized in the evaluation of adverse events following immunization. The case definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) as part of the Safety Platform for Emergency vACcines (SPEAC) project, in the context of active development of vaccines for COVID-19 and other emerging pathogens. The case definition format of the Brighton Collaboration was followed to develop a consensus case definition and defined levels of diagnostic certainty, after an exhaustive review of the literature and expert consultation.

The revised Brighton Case Definition for Anaphylaxis was submitted to Vaccine on October 17th, 2022.


Click here to access the publication in Vaccine

Companion Guide

Click here to view the Companion Guide

This case definition companion guide collates into a single document the SPEAC Thrombosis and Thromboembolism resources (Risk factors, background rates, ICD9/10-CM & MedDRA codes), tools (data abstraction & interpretation form, tabular summary of key case definition criteria and algorithm for level of certainty determination, pictorial level of certainty algorithm) and guidance (real-time investigation, data collection, analysis and presentation).

More Case Definitions